Coagulopathy in Acute Promyelocytic Leukemia: Can We Go Beyond Supportive Care?

Acute promyelocytic leukemia (APL) is characterized by frequent complications due to a distinct coagulopathy. While advances in treatments have improved long-term survival, hemorrhagic and thrombotic complications remain the most common causes of death and morbidity. Improved understanding of the me...

Descripción completa

Detalles Bibliográficos
Autores principales: Hambley, Bryan C., Tomuleasa, Ciprian, Ghiaur, Gabriel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415964/
https://www.ncbi.nlm.nih.gov/pubmed/34485349
http://dx.doi.org/10.3389/fmed.2021.722614
_version_ 1783748075679907840
author Hambley, Bryan C.
Tomuleasa, Ciprian
Ghiaur, Gabriel
author_facet Hambley, Bryan C.
Tomuleasa, Ciprian
Ghiaur, Gabriel
author_sort Hambley, Bryan C.
collection PubMed
description Acute promyelocytic leukemia (APL) is characterized by frequent complications due to a distinct coagulopathy. While advances in treatments have improved long-term survival, hemorrhagic and thrombotic complications remain the most common causes of death and morbidity. Improved understanding of the mechanisms of the coagulopathy associated with APL may lead to therapeutic interventions to mitigate the risk of hemorrhage and thrombosis.
format Online
Article
Text
id pubmed-8415964
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84159642021-09-04 Coagulopathy in Acute Promyelocytic Leukemia: Can We Go Beyond Supportive Care? Hambley, Bryan C. Tomuleasa, Ciprian Ghiaur, Gabriel Front Med (Lausanne) Medicine Acute promyelocytic leukemia (APL) is characterized by frequent complications due to a distinct coagulopathy. While advances in treatments have improved long-term survival, hemorrhagic and thrombotic complications remain the most common causes of death and morbidity. Improved understanding of the mechanisms of the coagulopathy associated with APL may lead to therapeutic interventions to mitigate the risk of hemorrhage and thrombosis. Frontiers Media S.A. 2021-08-17 /pmc/articles/PMC8415964/ /pubmed/34485349 http://dx.doi.org/10.3389/fmed.2021.722614 Text en Copyright © 2021 Hambley, Tomuleasa and Ghiaur. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Hambley, Bryan C.
Tomuleasa, Ciprian
Ghiaur, Gabriel
Coagulopathy in Acute Promyelocytic Leukemia: Can We Go Beyond Supportive Care?
title Coagulopathy in Acute Promyelocytic Leukemia: Can We Go Beyond Supportive Care?
title_full Coagulopathy in Acute Promyelocytic Leukemia: Can We Go Beyond Supportive Care?
title_fullStr Coagulopathy in Acute Promyelocytic Leukemia: Can We Go Beyond Supportive Care?
title_full_unstemmed Coagulopathy in Acute Promyelocytic Leukemia: Can We Go Beyond Supportive Care?
title_short Coagulopathy in Acute Promyelocytic Leukemia: Can We Go Beyond Supportive Care?
title_sort coagulopathy in acute promyelocytic leukemia: can we go beyond supportive care?
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415964/
https://www.ncbi.nlm.nih.gov/pubmed/34485349
http://dx.doi.org/10.3389/fmed.2021.722614
work_keys_str_mv AT hambleybryanc coagulopathyinacutepromyelocyticleukemiacanwegobeyondsupportivecare
AT tomuleasaciprian coagulopathyinacutepromyelocyticleukemiacanwegobeyondsupportivecare
AT ghiaurgabriel coagulopathyinacutepromyelocyticleukemiacanwegobeyondsupportivecare

Ejemplares similares